TGFBR1 and cancer: Vactosertib (EW-7197) was developed and characterized in 2014 [404] as a highly potent and bioavailable kinase inhibitor of TβRI, with potent biological effects (IC50 = 12.1 to 16.5 nM) inhibiting responses in various cancer cell line models.